D1.1 JA PCM-SPARC synergy I

Frederickx, Nancy; Van Valckenborgh, Els; Waeytens, Anouk; Barthélémy, Moreau de Lizoreux; Dessing, Lieve; Ottaviano, Manuel; Denis Horgan; Pazzagli, Sofia; Uribe, Silvia; Van den Bulcke, Marc

doi:10.5281/zenodo.18787137

Published February 26, 2026 | Version V1

Project deliverable Open

D1.1 JA PCM-SPARC synergy I

1. Sciensano
2. Universidad Politecnica de Madrid
3. European Alliance for Personalised Medicine
4. Universidad Politécnica de Madrid

Contributors

Project members:

1. Vall d'Hebron Institute of Oncology
2. Instituto de Investigación Sanitaria La Fe
3. Lungs Europe
4. European Alliance for Personalised Medicine
5. Association of European Cancer Leagues
6. National Melanoma Society
7. ELLOK
8. Sciensano
9. Aarhus University
10. Fondazione Policlinico Gemelli
11. The Netherlands Cancer Institute
12. ISLB
13. UNIFI
14. IHU RespirERA
15. Institut Gustave Roussy
16. Istituto Superiore di Sanità
17. INSA
18. Helenic Cancer Federation - ELLOK

This report outlines the first milestone in the structured collaboration between the Joint Action on Personalised Cancer Medicine (JA PCM) and the SPARC project (Support of Personalised Medicine Approaches in Cancer). Both initiatives share the overarching goal of accelerating the adoption, integration, and equitable implementation of personalised cancer medicine (PCM) across Europe. While JA PCM addresses the entire patient pathway from prevention, diagnosis and treatment to follow-up, and provides broad European coverage, policy reach, and system-level coordination, SPARC complements this shared goal with strong patient engagement, stakeholder participation, pilot-driven clinical evidence, and targeted activities in the diagnosis and treatment area including liquid biopsy, molecular tumour boards and training. The European Commission has mandated a formal synergy between the two initiatives, which has been structured around three deliverables and three milestones. This document represents the first tangible result.

To enable effective collaboration, a joint synergy strategy was developed through a series of alignment meetings between the coordination teams. This strategy is built on three pillars:

● Integration of patient perspectives,

● Three thematic Working Groups (Liquid Biopsy & NGS, Molecular Tumor Boards, Education & Training),

● A stakeholder engagement, communication and dissemination strategy.

This first deliverable establishes the governance, shared priorities, and operational framework for the JA PCM-SPARC synergy. The next phase will focus on implementing the agreed synergy actions throughout 2026, launching the patient advisory and consultation mechanisms, running the Working Groups, deploying the stakeholder engagement model, and monitoring progress to ensure the effective, equitable, and sustainable integration of personalised cancer medicine across Europe.

Files